BC Week In Review | Mar 18, 2013
Clinical News

Limtop imiquimod: Development discontinued

Moberg discontinued development of Limtop after data from a double-blind, placebo-controlled, German Phase II trial in 97 patients with actinic keratosis showed that Limtop did not meet the predefined efficacy target. Moberg declined to disclose...
BC Week In Review | Dec 3, 2012
Company News

Alterna, Moberg Derma deal

Moberg acquired its U.S. distributor Alterna for about SEK133 million ($20 million) in a cash and stock deal. Moberg issued Alterna SEK33 million ($4.9 million), or 825,625 shares, in Moberg stock and paid about SEK100...
BC Week In Review | Sep 10, 2012
Clinical News

Limtop imiquimod: Completed Phase II enrollment

Moberg completed enrollment of 97 patients in a double-blind, placebo-controlled, German Phase II trial evaluating topical Limtop given 1, 3 or 7 times weekly. Moberg Derma AB (SSE:MOB), Bromma, Sweden   Product: Limtop imiquimod  ...
BioCentury | Aug 6, 2012
Finance

Glint of IPO optimism

Aftermarket performance is better for biotech IPOs this year than it was in 2011. Although the basics of what it takes to get an IPO done haven't changed - deals routinely continue to require a discount...
BC Week In Review | Mar 19, 2012
Clinical News

Limtop: Phase I started

Moberg Derma began a double-blind, placebo-controlled, German Phase I trial to evaluate Limtop in 30 subjects. Moberg Derma AB (SSE:MOB), Bromma, Sweden   Product: Limtop   Business: Cancer, Dermatology, Infectious   Molecular target: NA  ...
BioCentury | Mar 19, 2012
Finance

Highlights of weekly biotech stock moves

Active Biotech AB (SSE:ACTI) gained SEK9.70 (24%) to SEK49.40 on Thursday after partner Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) said it plans to submit an MAA to EMA in 2H12 for laquinimod in multiple sclerosis (MS)....
BC Week In Review | Feb 20, 2012
Clinical News

MOB-015: Preliminary Phase II data

Moberg said an analysis of about 50% of the patients in an open-label, Swedish Phase II trial of once-daily topical MOB-015 showed that there is a "low probability that the final results will be sufficient...
BioCentury | Oct 3, 2011
Finance

Cost averaging down

Even the best fundamentals may not be able to overcome the negative effects of the broader economy on the stock market this quarter. As a result, specialists have little hope of major gains and instead...
BC Week In Review | Sep 19, 2011
Clinical News

MOB-015: Completed Phase II enrollment

Moberg Derma completed enrollment of 237 patients in an open-label, Swedish Phase II trial evaluating once-daily topical MOB-015. Moberg Derma AB (SSE:MOB), Stockholm, Sweden   Product: MOB-015   Business: Infectious   Molecular target: NA  ...
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Hoping the rally has legs

Buysiders expect biotech may be able to continue to outperform the broader markets, despite a retreat from spring highs. In particular, they see two bright spots for the sector: selective gains on a full calendar...
Items per page:
1 - 10 of 32
BC Week In Review | Mar 18, 2013
Clinical News

Limtop imiquimod: Development discontinued

Moberg discontinued development of Limtop after data from a double-blind, placebo-controlled, German Phase II trial in 97 patients with actinic keratosis showed that Limtop did not meet the predefined efficacy target. Moberg declined to disclose...
BC Week In Review | Dec 3, 2012
Company News

Alterna, Moberg Derma deal

Moberg acquired its U.S. distributor Alterna for about SEK133 million ($20 million) in a cash and stock deal. Moberg issued Alterna SEK33 million ($4.9 million), or 825,625 shares, in Moberg stock and paid about SEK100...
BC Week In Review | Sep 10, 2012
Clinical News

Limtop imiquimod: Completed Phase II enrollment

Moberg completed enrollment of 97 patients in a double-blind, placebo-controlled, German Phase II trial evaluating topical Limtop given 1, 3 or 7 times weekly. Moberg Derma AB (SSE:MOB), Bromma, Sweden   Product: Limtop imiquimod  ...
BioCentury | Aug 6, 2012
Finance

Glint of IPO optimism

Aftermarket performance is better for biotech IPOs this year than it was in 2011. Although the basics of what it takes to get an IPO done haven't changed - deals routinely continue to require a discount...
BC Week In Review | Mar 19, 2012
Clinical News

Limtop: Phase I started

Moberg Derma began a double-blind, placebo-controlled, German Phase I trial to evaluate Limtop in 30 subjects. Moberg Derma AB (SSE:MOB), Bromma, Sweden   Product: Limtop   Business: Cancer, Dermatology, Infectious   Molecular target: NA  ...
BioCentury | Mar 19, 2012
Finance

Highlights of weekly biotech stock moves

Active Biotech AB (SSE:ACTI) gained SEK9.70 (24%) to SEK49.40 on Thursday after partner Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) said it plans to submit an MAA to EMA in 2H12 for laquinimod in multiple sclerosis (MS)....
BC Week In Review | Feb 20, 2012
Clinical News

MOB-015: Preliminary Phase II data

Moberg said an analysis of about 50% of the patients in an open-label, Swedish Phase II trial of once-daily topical MOB-015 showed that there is a "low probability that the final results will be sufficient...
BioCentury | Oct 3, 2011
Finance

Cost averaging down

Even the best fundamentals may not be able to overcome the negative effects of the broader economy on the stock market this quarter. As a result, specialists have little hope of major gains and instead...
BC Week In Review | Sep 19, 2011
Clinical News

MOB-015: Completed Phase II enrollment

Moberg Derma completed enrollment of 237 patients in an open-label, Swedish Phase II trial evaluating once-daily topical MOB-015. Moberg Derma AB (SSE:MOB), Stockholm, Sweden   Product: MOB-015   Business: Infectious   Molecular target: NA  ...
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Hoping the rally has legs

Buysiders expect biotech may be able to continue to outperform the broader markets, despite a retreat from spring highs. In particular, they see two bright spots for the sector: selective gains on a full calendar...
Items per page:
1 - 10 of 32